

**Saturday, October 12, 2019**

---

**6:30am**      **Registration and Continental Breakfast**

---

**7:00**      **Welcome**  
Jeffery E. Lee, MD

---

**7:05**      **The University of Texas MD Anderson  
Cancer Center Greeting**  
Peter WT Pisters, MD

## Melanoma

### *Emerging Approaches in the Management of Melanoma*

---

Session Chair: Hussein A. Tawbi, MD, PhD

---

**7:10**      **Session Introduction**  
Hussein A. Tawbi, MD, PhD

---

**7:20**      **Neoadjuvant Targeted and Checkpoint  
Therapy of Melanoma**  
Rodabe N. Amaria, MD

---

**7:40**      **Identifying and Overcoming Resistance  
to Melanoma Systemic Therapy**  
Michael A. Davies, MD, PhD

---

**8:00**      **Personalized Melanoma Surgery in the Modern Era:  
What are the Roles of SLNB and LND?**  
Jeffrey E. Gershenwald, MD

---

**8:20**      **Cases**  
Moderator: Emily Z. Keung, MD

---

**8:50**      **Break**

## Breast

### *Individualizing Multidisciplinary Breast Cancer Care*

---

Session Chair: Henry M. Kuerer, MD, PhD

---

**9:00**      **Session Introduction**  
Henry M. Kuerer, MD, PhD

|       |                                                                                                                                    |
|-------|------------------------------------------------------------------------------------------------------------------------------------|
| 9:10  | <b>Integrating Breast Reconstructive Surgery when Post-Mastectomy Radiotherapy is Indicated</b><br>Mark V. Schaverien, MD          |
| 9:30  | <b>Updates on PARP Inhibitors and Immunotherapy for Breast Cancer</b><br>Bora Lim, MD                                              |
| 9:50  | <b>Targeted Axillary Dissection (TAD) and Surgical Management of the Axilla after Neoadjuvant Therapy</b><br>Abigail S. Caudle, MD |
| 10:10 | <b>Advances in the Management of HER-2 Positive Breast Cancer</b><br>Rashmi K. Murthy, MD                                          |
| 10:30 | <b>Cases</b><br>Moderator: Rosa F. Hwang, MD                                                                                       |
| 11:00 | <b>Lunch (provided)</b>                                                                                                            |

## Gynecologic Oncology

### *Innovations and Controversies in Gynecologic Oncology*

Session Chair: Amir A. Jazaeri, MD

|          |                                                                                                                            |
|----------|----------------------------------------------------------------------------------------------------------------------------|
| 11:15    | <b>Session Introduction</b><br>Amir A. Jazaeri, MD                                                                         |
| 11:25    | <b>Controversies and Outcomes in Minimally Invasive Surgery in Gynecologic Oncology</b><br>Jose A. Rauh-Hain, MD           |
| 11:45    | <b>Integrating SLN Biopsy Into the Management of Patients with Endometrial Cancer</b><br>Michael M. Frumovitz, MD          |
| 12:05 pm | <b>Increasing HPV Vaccine Confidence and Understanding HPV Vaccine Efficacy and Indications*</b><br>Lois M. Ramondetta, MD |
| 12:25    | <b>Cases</b><br>Moderator: Larissa A. Meyer, MD                                                                            |
| 12:55    | <b>Break</b>                                                                                                               |

## Gastrointestinal Tumors

### *Management of Gastrointestinal Cancer in 2019: Personalizing Care with Targets, Strategies and Sequencing*

Session Chair: Matthew H. G. Katz, MD

|      |                                                                                                      |
|------|------------------------------------------------------------------------------------------------------|
| 1:05 | <b>Session Introduction</b><br>Matthew H. G. Katz, MD                                                |
| 1:15 | <b>Advances in Targeted Therapy for Neuroendocrine Tumors</b><br>Daniel M. Halperin, MD              |
| 1:35 | <b>Role of Immunotherapy for Gastrointestinal Cancers</b><br>Michael J. Overman, MD                  |
| 1:55 | <b>Progress in Adjuvant and Neoadjuvant Treatment of Pancreatic Cancer</b><br>Ching-Wei D. Tzeng, MD |
| 2:15 | <b>Cases</b><br>Moderator: Naruhiko Ikoma, MD                                                        |
| 2:45 | <b>Break</b>                                                                                         |

## Genitourinary Tumors

### *Individualized Management of Patients with GU Malignancies: A 2019 Update*

Session Chair: Jose A. Karam, MD

|         |                                                                                                            |
|---------|------------------------------------------------------------------------------------------------------------|
| 2:55    | <b>Session Introduction</b><br>Jose A. Karam, MD                                                           |
| 3:05    | <b>Advances in the Management of Aggressive Variant Prostate Cancer</b><br>Paul G. Corn, MD, PhD           |
| 3:25    | <b>Choice of First-Line Systemic Therapy in Metastatic Renal Cell Carcinoma</b><br>Matthew T. Campbell, MD |
| 3:45    | <b>Management of Patients with Non-Muscle Invasive Bladder Cancer: 2019 and Beyond</b><br>Neema Navai, MD  |
| 4:05    | <b>Cases</b><br>Moderator: Brian F. Chapin, MD                                                             |
| 4:35 pm | <b>Adjourn</b>                                                                                             |

## Evening Keynote Presentations

Location: Marriott Marquis Houston

5:30 **CAR NK Cell Therapy**  
Katy Rezvani, MD, PhD

6:00 **The Promise of Liquid Biopsy in Cancer Care**  
Scott Kopetz, MD, PhD

6:30 **Reception**

7:30 pm **Adjourn**

*\*Indicates ethics credit*

**Sunday, October 13, 2019**

6:30 am **Registration and Continental Breakfast**

7:00 **Keynote Presentation: The Role of the Microbiome in the Response to Immunotherapy**  
Jennifer Wargo, MD

## Leukemia and Lymphoma

### Hematologic Malignancies: 2019 State of the Art Care

Session Chair: Jason R. Westin, MD

7:30 **Session Introduction**  
Jason R. Westin, MD

7:40 **Indications for Subcutaneous Cellular Tissue in AML, CML, and MDS in the Era of Targeted Therapy**  
Richard E. Champlin, MD

8:00 **Novel Treatment Strategies in B-Cell Lymphoma**  
Jason R. Westin, MD

8:20 **Selecting Treatment for Patients with Multiple Myeloma**  
Robert Z. Orlowski, MD, PhD

8:40 **Cases**  
Moderator: Loretta J. Nastoupil, MD

9:00 **Break**

## Thoracic Cancers

### Update on the Management of Thoracic Malignancies, Lung, Esophagus and metastatic Disease of the Lung

Session Chair: Reza J. Mehran, MD

9:10 **Session Introduction**  
Reza J. Mehran, MD

9:20 **Advances in the Treatment of Metastatic NSCLC**  
John V. Heymach, MD, PhD

9:40 **Location Therapy of Oligo-Metastatic Disease of the Lung: Surgery vs. SABR vs. RFA**  
Reza J. Mehran, MD

10:00 **Esophageal Cancer: Results and Role of Salvage Surgery**  
Wayne L. Hofstetter, MD

10:20 **Cases**  
Moderator: Boris Sepesi, MD

10:50 **Break**

## Endocrine Cancers

### Targeted Treatment Strategies for Thyroid Cancer

Session Chair: Mimi I-Nan Hu, MD

11:00 **Session Introduction**  
Mimi I-Nan Hu, MD

11:10 **Multidisciplinary Management to Improve Outcomes of Patients with Anaplastic Thyroid Cancer**  
Maria E. Cabanillas, MD

11:30 **Integrating Molecular Diagnostics Into the Diagnosis and Management of Thyroid Cancer**  
Elizabeth G. Grubbs, MD

|          |                                                                                                            |
|----------|------------------------------------------------------------------------------------------------------------|
| 11:50    | <b>Cases</b><br>Moderator: Mark E. Zafereo, Jr., MD                                                        |
| 12:20 pm | <b>Lunch (provided)</b>                                                                                    |
| 12:35    | <b>Keynote Presentation:</b><br><b>Emerging Actionable Genomic Alterations</b><br>Funda Meric-Bernstam, MD |

## Brain Metastases

### *Hope, Opportunity and Cure in the Treatment of Brain Metastases*

Session Chair: Michael K. Wong, MD, PhD

|         |                                                                                                       |
|---------|-------------------------------------------------------------------------------------------------------|
| 1:05    | <b>Session Introduction</b><br>Michael K. Wong, MD, PhD                                               |
| 1:15    | <b>Multidisciplinary Management of Melanoma Brain Metastases</b><br>Isabella C. Glitza Oliva, MD, PhD |
| 1:35    | <b>Stereotactic Radiosurgery vs Surgery for Brain Metastases</b><br>Jeffrey S. Weinberg, MD           |
| 1:55    | <b>Cases</b><br>Moderator: Michael K. Wong, MD, PhD                                                   |
| 2:25    | <b>Closing Remarks</b>                                                                                |
| 2:30 pm | <b>Adjourn</b>                                                                                        |

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.